🔗 Share this article America and Britain Finalize No-Tariff Agreement on Pharmaceuticals. Stock image of drug exports. The UK and US have announced a significant bilateral deal that will maintain no duties on UK drug products going into the American market. Agreement Details of the Accord As part of the deal, the UK has agreed to boost funding on drugs through the public health system. This commitment secures that import taxes on these crucial products will remain at zero for a timeframe of three years. This deal comes after recent warnings to hike duties on branded drug imports, with potential rates discussed up to double the cost. "This arrangement with the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed fairness to American-British pharmaceutical trade," a release said. Economic Impact Drugs represent one of the the United Kingdom's biggest export categories to the United States, which is easily the biggest destination for leading companies like GSK and AstraZeneca. Statistics show that in the one-year period to the end of the third quarter, the UK exported medicines totaling £11.1bn to the US. This amount made up 17.4% of total UK exports in that span. "This deal safeguards work, stimulates capital expenditure and sets the stage for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary stated. Detailed British Pledges The agreement entails several notable commitments from the United Kingdom: Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be prohibitively costly by twenty-five percent. Higher Drug Budget: There is a goal to double total NHS spending on medicines from 0.3% of the national economy to 0.6% over the coming ten years. Payback Limit: The sum manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments topped twenty percent. Broader Context This agreement comes amid a ongoing tension between the pharmaceutical industry and the UK government over drug pricing and NHS adoption. These tensions were intensified by claims that US customers were paying significantly more for the same drugs than consumers in the Britain and the EU. Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been announced toward US facilities. The Science Minister acknowledged that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the last ten years.
Stock image of drug exports. The UK and US have announced a significant bilateral deal that will maintain no duties on UK drug products going into the American market. Agreement Details of the Accord As part of the deal, the UK has agreed to boost funding on drugs through the public health system. This commitment secures that import taxes on these crucial products will remain at zero for a timeframe of three years. This deal comes after recent warnings to hike duties on branded drug imports, with potential rates discussed up to double the cost. "This arrangement with the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed fairness to American-British pharmaceutical trade," a release said. Economic Impact Drugs represent one of the the United Kingdom's biggest export categories to the United States, which is easily the biggest destination for leading companies like GSK and AstraZeneca. Statistics show that in the one-year period to the end of the third quarter, the UK exported medicines totaling £11.1bn to the US. This amount made up 17.4% of total UK exports in that span. "This deal safeguards work, stimulates capital expenditure and sets the stage for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary stated. Detailed British Pledges The agreement entails several notable commitments from the United Kingdom: Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be prohibitively costly by twenty-five percent. Higher Drug Budget: There is a goal to double total NHS spending on medicines from 0.3% of the national economy to 0.6% over the coming ten years. Payback Limit: The sum manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments topped twenty percent. Broader Context This agreement comes amid a ongoing tension between the pharmaceutical industry and the UK government over drug pricing and NHS adoption. These tensions were intensified by claims that US customers were paying significantly more for the same drugs than consumers in the Britain and the EU. Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been announced toward US facilities. The Science Minister acknowledged that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the last ten years.